Thus, YTHDF2 links RNA epitranscriptomic modifications and GSCs growth, laying the foundation for the YTHDF2–MYC–IGFBP3 axis as a specific and novel therapeutic target in glioblastoma [36]. The gene discussed is YTHDF2; the disease is glioblastoma.